{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:21:01Z","timestamp":1760548861765,"version":"3.37.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1097\/ftd.0b013e3181b777f9","type":"journal-article","created":{"date-parts":[[2009,9,22]],"date-time":"2009-09-22T07:18:02Z","timestamp":1253603882000},"page":"592-596","source":"Crossref","is-referenced-by-count":15,"title":["Formulations of Valproate Alter Valproate Metabolism: A Single Oral Dose Kinetic Study"],"prefix":"10.1097","volume":"31","author":[{"given":"Goyo","family":"Nagai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Yasui-Furukori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Mihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-10-20210129","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/hep.1840020513","article-title":"Valproate-induced hepatic injury: analyses of 23 fatal cases.","volume":"2","author":"Zimmerman","year":"1982","journal-title":"Hepatology"},{"key":"R2-10-20210129","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/hep.1840040609","article-title":"The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies.","volume":"4","author":"Kesterson","year":"1984","journal-title":"Hepatology"},{"key":"R3-10-20210129","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1212\/WNL.37.3.379","article-title":"Valproic acid hepatic fatalities: a retrospective review.","volume":"37","author":"Dreifuss","year":"1987","journal-title":"Neurology"},{"key":"R4-10-20210129","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(82)90908-4","article-title":"Maternal valproic acid and congenital neural tube defects.","volume":"2","author":"Robert","year":"1982","journal-title":"Lancet"},{"key":"R5-10-20210129","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0022-3476(86)80949-0","article-title":"Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid.","volume":"108","author":"Jager-Roman","year":"1986","journal-title":"J Pediatr"},{"key":"R6-10-20210129","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1528-1157.1988.tb03746.x","article-title":"Teratogenicity of antiepileptic drugs: analysis of possible risk factors.","volume":"29","author":"Kaneko","year":"1988","journal-title":"Epilepsia"},{"key":"R7-10-20210129","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1528-1157.1980.tb04323.x","article-title":"Hepatotoxicity of sodium valproate and other anticonvulsants in rat hepatocyte cultures.","volume":"21","author":"Kingsley","year":"1980","journal-title":"Epilepsia"},{"key":"R8-10-20210129","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1016\/0024-3205(81)90541-5","article-title":"A new model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrations.","volume":"29","author":"Nau","year":"1981","journal-title":"Life Sci"},{"issue":"Suppl 4","key":"R9-10-20210129","first-page":"41","article-title":"Teratogenicity of valproate: pharmacokinetic aspects.","volume":"2","author":"Kondo","year":"1995","journal-title":"Eur J Neurol"},{"key":"R10-10-20210129","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jocn.2004.05.003","article-title":"Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy.","volume":"11","author":"Vajda","year":"2004","journal-title":"J Clin Neurosci"},{"key":"R11-10-20210129","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1212\/01.wnl.0000227919.81208.b2","article-title":"In utero antiepileptic drug exposure: fetal death and malformations.","volume":"67","author":"Meador","year":"2006","journal-title":"Neurology"},{"issue":"Suppl 1","key":"R12-10-20210129","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1111\/j.1528-1157.1984.tb05632.x","article-title":"Valproic acid and metabolites: pharmacological and toxicological studies.","volume":"25","author":"Nau","year":"1984","journal-title":"Epilepsia"},{"key":"R13-10-20210129","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3109\/00498258709167407","article-title":"Studies on the metabolic fate of valproic acid in the rat using stable isotope techniques.","volume":"17","author":"Rettenmeier","year":"1987","journal-title":"Xenobiotica"},{"key":"R14-10-20210129","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1126\/science.3101178","article-title":"Cytochrome P-450-catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid.","volume":"235","author":"Rettie","year":"1987","journal-title":"Science"},{"key":"R15-10-20210129","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0022-3565(24)37076-4","article-title":"Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid.","volume":"283","author":"Sadeque","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"R16-10-20210129","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.tpj.6500210","article-title":"Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes.","volume":"3","author":"Ho","year":"2003","journal-title":"Pharmacogenomics J"},{"key":"R17-10-20210129","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/BF00445664","article-title":"Abnormal metabolism of valproic acid in fatal hepatic failure.","volume":"141","author":"Kochen","year":"1983","journal-title":"Eur J Pediatr"},{"key":"R18-10-20210129","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0009-8981(85)90280-3","article-title":"Altered metabolic profiles of valproic acid in a patient with Reyes syndrome.","volume":"145","author":"Kuhara","year":"1985","journal-title":"Clin Chim Acta"},{"key":"R19-10-20210129","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1528-1157.1992.tb02302.x","article-title":"Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism.","volume":"33","author":"Kondo","year":"1992","journal-title":"Epilepsia"},{"key":"R20-10-20210129","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3999\/jscpt.19.749","article-title":"Pharmacokinetics of valproic acid and its metabolites after a single oral administration of a sustained-release preparation of sodium valproate (KW-6066N) [in Japanese, abstract in English].","volume":"19","author":"Tatsuhara","year":"1988","journal-title":"Jpn J Clin Pharmacol Ther"},{"key":"R21-10-20210129","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1034\/j.1600-0773.2002.900304.x","article-title":"Altered pharmacokinetics and metabolism of valproate after replacement of conventional valproate with the slow-release formulation in epileptic patients.","volume":"90","author":"Kondo","year":"2002","journal-title":"Pharmacol Toxicol"},{"key":"R22-10-20210129","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0378-4347(00)84207-3","article-title":"Valproic acid and several metabolites: quantitative determination in serum, urine, breast milk and tissues by gas chromatography-mass spectrometry using selected ion monitoring.","volume":"226","author":"Nau","year":"1981","journal-title":"J Chromatogr"},{"key":"R23-10-20210129","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1365-2125.1990.tb03610.x","article-title":"The effects of phenytoin and carbamazepine on serum concentrations of mono-unsaturated metabolites of valproic acid.","volume":"29","author":"Kondo","year":"1990","journal-title":"Br J Clin Pharmacol"},{"key":"R24-10-20210129","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0041-008X(85)90081-X","article-title":"Teratogenic valproic acid concentrations: infusion by implanted minipumps vs conventional injection regimen in the mouse.","volume":"80","author":"Nau","year":"1985","journal-title":"Toxicol Appl Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e3181b777f9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T08:42:14Z","timestamp":1739349734000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-200910000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3181b777f9","relation":{},"ISSN":["0163-4356"],"issn-type":[{"type":"print","value":"0163-4356"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}